A $75 million settlement has been granted preliminary approval in the class action lawsuit filed on behalf of all persons or entities who purchased Relafen or its generic alternative, nabumetone, from September 1, 1998 to June 30, 2003. The suit alleged that Relafen's distributors unlawfully obtained a patent which allowed them to enforce a monopoly over Relafen and prevent competition by generic prescription drugs. (Dec-01-04)
[PR NEWSWIRE] [EMAIL LAW FIRM]
Stay Informed
Get the latest on class action lawsuits, settlements & more! Subscribe to our free weekly newsletter.
Get our Newsletter!
Submit a New Complaint
Been wronged by a similar product or service?
Click here to send us your complaint.
